Role of CTSC in Glioblastoma Based on Oncomine and TCGA Database
Background and objective Glioblastoma (GBM) is one of the malignant tumors causing death worldwide. Most patients were found in the middle and late stages and had poor prognosis. The purpose of this study was to investigate the expression and significance of CTSC in GBM.
Methods The information about CTSC in Oncomine database was collected and analyzed twice. The role of CTSC in GBM was meta-analyzed. The expression of CTSC in glioma cell lines was retrieved by CCLE database, and the survival of patients was analyzed by TCGA database.
Results A total of 1,459 different types of CTSC were collected in Oncomine database, 134 of which had statistical differences in CTSC expression, 89 of which had increased CTSC expression and 45 of which had decreased CTSC expression. A total of 50 studies involving the expression of CTSC in GBM cancer and normal tissues included 1,189 samples.
Compared with the control group, CTSC was highly expressed in GBM (P < 0.05). Moreover, CTSC was highly expressed in glioma cell lines. There was a correlation between the expression of CTSC and the overall survival rate of GBM. The overall survival rate of patients with high expression of CTSC was worse, while the prognosis of patients with low expression of SPC24 was better (P < 0.05).
Conclusion Through the in-depth mining of oncomine gene chip database, we propose that CTSC is highly expressed in GBM tissues and is related to the prognosis of GBM, which may provide an important theoretical basis for the treatment of glioma.